Cat. No.: X23-10-ZQ368
JAK inhibitor Tofacitinib citrate, Purity ≥98%
Synonym: Tofacitinib citrate; 540737-29-9; Tasocitinib citrate; Xeljanz; CP-690550 citrate; Tofacitinib (citrate); Tofacitinib (CP-690550) citrate; JAK inhibitor
- MDL: MFCD11616529
- CAS Number: 540737-29-9
- Compound CID: 10174505
Product Size
10 mg; 25 mg; 50 mg; 100 mg
Properties
Description
Tofacitinib citrate, soluble in warmed DMSO and insoluble in water and ethanol, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, JAK2, AMPK, CDK2, CDK2/CyclinA, Chk1, CK2, CSK, EGFR, GSK-3β, and IRK.
Molecular Formula
C16H20N6O.C6H8O7
Targets
JAK1: 112 nM; JAK2: 20 nM; AMPK: >10 μM; CDK2: >10 μM; CDK2/CyclinA: >10 μM; Chk1: >10 μM; CK2: >10 μM; CSK: >10 μM; EGFR: >10 μM; GSK-3β: >10 μM; IRK: >10 μM
Solubility
Warmed DMSO: 94 mg/mL (186.32 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
Tofacitinib citrate is used in research focusing on its JAK1/3 inhibition properties for treating rheumatoid arthritis and other inflammatory diseases.
Related Products
-
JAK inhibitor JAK/HDAC-IN-1, Purity ≥98%
-
JAK inhibitor 1,2,3,4,5,6-Hexabromocyclohexane, Purity ≥98%
-
JAK inhibitor Abrocitinib, Purity ≥98%
-
JAK inhibitor AZ-3, Purity ≥98%
-
JAK inhibitor AZ-960, Purity ≥98%
-
JAK inhibitor AZD1480, Purity ≥98%
Quick Links